Skip to main content
. 2018 Dec 10;13(12):e0208725. doi: 10.1371/journal.pone.0208725

Table 3. Summary of the meta-analysis of thromboprophylaxis safety following CS.

subgroup Included studies N Bleeding/ haematomas N Blood transfusion N Wound complications N Allergic reactions
RR (95% CI) I2 P(%) RR (95% CI) I2 P(%) RR (95% CI) I2 P(%) RR (95% CI) I2 P(%)
LMWH versus negative control overall 4 8.47 (1.52–47.11) 0 0.01 3 2.48(0.04–146) 73 0.66 3 2.42(0.71–8. 24) 0 0.16 3 NE NA NA
RCTs 3 6.17(0.76–49.96) NA 0.09 2 0.32(0.01–7.54) NA 0.48 2 1.94(0.50–7.44) 0 0.34 3 NE NA NA
Cohort 1 11.89(0.70–200.7) NA 0.09 1 17.07(1.03–282) NA 0.05 1 4.65(0.25–85.97) NA 0.30 0
Unknown risk of VTE 4 8.47 (1.52–47.11) 0 0.01 3 2.48(0.04–146) 73 0.66 3 2.42(0.71–8. 24) 0 0.16 3 NE NA NA
LMWH versus UFH overall 2 NE NA NA 0 0 1 NE NA NA
RCTs 2 NE NA NA 0 0 1 NE NA NA
Unknown risk of VTE 1 NE NA NA 0 0 1 NE NA NA
high risk of VTE 1 NE NA NA 0 0 0
LMWH versus LMWH overall 3 NE NA NA 0 0 2 NE NA NA
RCTs 3 NE NA NA 0 0 2 NE NA NA
high risk of VTE 3 NE NA NA 0 0 2 NE NA NA

Abbreviations: N, number of studies; OR, odds ratio; CI, confidence interval; P, P value for association; NE, not estimable; NA, not applicable